Plain-English translation of NCT06989723 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 2 Diabetes research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether pioglitazone and empagliflozin work better together than either one alone for treating fatty liver disease in people with type 2 diabetes. Both medications have helped patients individually, but doctors want to know if combining them offers even greater benefits for liver health. The study will measure whether the combination reduces fat buildup, inflammation, and scarring in the liver.
Many people with type 2 diabetes develop fatty liver disease, which can lead to serious liver damage over time. While each of these medications has shown promise on its own, doctors don't yet know whether using them together might offer better protection for the liver.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either pioglitazone alone, empagliflozin alone, or both medications together as a daily pill. During the study, you will have regular visits to the hospital where doctors will check your blood work, measure your liver health using ultrasound scans, and monitor how well the treatment is working. The study will track how the medication affects your liver fat, inflammation, and overall diabetes control over time.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
South Korea